Efficacy of a 20:1 CBD:THC cannabis herbal extract for pain and inflammation in dogs following tibial plateau leveling osteotomy.

Oral 20:1 CBD:THC extract did not enhance pain relief or mobility post-TPLO in dogs.

This study evaluated the efficacy of a 20:1 cannabidiol (CBD) to tetrahydrocannabinol (THC) cannabis herbal extract (CHE) in reducing pain and improving mobility in dogs undergoing tibial plateau leveling osteotomy (TPLO) for cranial cruciate ligament rupture (CCLr). A total of 48 cases were initially enrolled, with 42 cases included in the final analysis. Six cases were excluded due to various reasons, including lack of follow-up visits and other factors. The study found that all dogs experienced marked improvement in owner-reported pain scores from days +1 to +14, regardless of the treatment group. However, there were no significant differences in outcome measures between the treatment groups. Potential treatment × day interactions were noted for range of motion (ROM) and gait symmetry; the high CHE dose group had marginally greater function on day +1, but none of these effects persisted to day +14. No serious adverse events were reported; mild gastrointestinal effects (vomiting or diarrhea) were noted in seven cases. Owners reported that the CHE doses were generally well tolerated. Plasma cannabinoid concentrations were highly variable and did not correlate with clinical outcomes. Overall, the administration of an oral 20:1 CBD:THC cannabis herbal extract in addition to a standard analgesic protocol did not improve analgesia and limb function following TPLO surgery in dogs. Minor functional benefits may have occurred in the higher CHE dose group, but only on the first day following surgery. Current multimodal peri- and post-operative analgesic practices were effective, irrespective of CHE administration. ([frontiersin.org](https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1676779/full?utm_source=openai))

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.